Compare BigBearai Holdings Inc (BBAI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Sana Biotechnology Inc — how do they compare? BigBearai Holdings Inc trades at $3.27 (market cap $1.60B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: BigBearai Holdings Inc is the larger of the two by market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | SANA | |
|---|---|---|
Market Cap | $1.60B | $1.13B |
Sector | Technology | Health |
52-Week High | $8.91 | $5.92 |
52-Week Low | $2.61 | $2.68 |
Enterprise Value | $1.30B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.26, up 0.93% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations, continuing negative profitability trends. Recent news highlights defense contract wins and generative AI platform expansion, while analyst consensus remains cautious with 75% hold ratings.
The outlook remains challenging with persistent losses and negative cash flow projections for 2026. Investment opportunity lies in defense AI specialization and backlog growth, but risks include execution challenges, high valuation multiples, and dependence on government contracts. The stock requires careful monitoring of profitability improvements.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
